Cure8 research brief
If you have isolated perianal fistulizing Crohn’s disease, this large multicenter cohort shows about one-third later developed luminal Crohn’s disease over long-term follow-up, but many did not — underscoring variable outcomes and the value of careful monitoring.
Patients with perianal Crohn’s disease, gastroenterologists, colorectal surgeons, and researchers focused on perianal disease progression.
This multicenter retrospective cohort study from the ECCO-CONFER network describes 121 adults who presented with isolated perianal fistulizing Crohn’s disease (IPFCD) and no luminal disease at baseline, followed for a median of 76 months.
Most patients underwent colonoscopy and pelvic MRI, treatment was commonly combined medical–surgical, and biologic therapy was used in a majority. About 57% achieved complete clinical remission and 46% had radiologic healing of fistulae.
Over long-term follow-up, roughly one-third (34.7%) progressed to luminal Crohn’s disease, typically several years after initial presentation; median time to luminal diagnosis reported was 110 months. The study found no consistent predictors of progression.
These findings highlight that IPFCD has a heterogeneous course: many remain free of intestinal involvement long-term, while a substantial minority later develop luminal disease. The authors emphasize variable diagnostic pathways and the need for standardized evaluation and better risk stratification.
Study is a retrospective multicenter cohort (ECCO-CONFER) summarized from the journal abstract; it describes associations and long-term outcomes but is not a prospective trial. No consistent predictors of progression were identified in the abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article outlines complications that can come from Crohn’s disease, many of which may need tests, medication, or surgery. Knowing these helps you recognize warning signs and talk with your care team about prevention...
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
